Abstract
As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus; whether through infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ability to measure SARS-CoV-2 immunity, ideally with rapid turnaround and without the need for laboratory-based testing. Current rapid point-of-care (POC) tests measure antibodies (Ab) against the SARS-CoV-2 virus, however, these tests provide no information on whether the antibodies can neutralise virus infectivity and are potentially protective, especially against newly emerging variants of the virus. Neutralising Antibodies (NAb) are emerging as a strong correlate of protection, but most current NAb assays require many hours or days, samples of venous blood, and access to laboratory facilities, which is especially problematic in resource-limited settings. We have developed a lateral flow POC test that can measure levels of RBD-ACE2 neutralising antibodies from whole blood, with a result that can be determined by eye (semi-quantitative) or on a small instrument (quantitative), and results show high correlation with microneutralisation assays. This assay also provides a measure of total anti-RBD antibody, thereby providing evidence of exposure to SARS-CoV-2 or immunisation, regardless of whether NAb are present in the sample. By testing samples from immunised macaques, we demonstrate that this test is equally applicable for use with animal samples, and we show that this assay is readily adaptable to test for immunity to newly emerging SARS-CoV-2 variants. Lastly, using a cohort of vaccinated humans, we demonstrate that our whole-blood test correlates closely with microneutralisation assay data (R2 =0.75, p<0.0001), and that fingerprick whole blood samples are sufficient for this test. Accordingly, the COVID-19 NAb-test™ device described here can provide a rapid readout of immunity to SARS-CoV-2 at the point of care.
Competing Interest Statement
A provisional patent covering the COVID-19 NAb-testTM test and underlying technology has been submitted through The University of Melbourne.
Funding Statement
We are grateful to the volunteers who provided samples for study. The authors would like to the Australian Red Cross Lifeblood for the supply of specimens from COVID-19 convalescent plasma donors. Australian Governments fund the Australian Red Cross Lifeblood to provide blood, blood products and services to the Australian community. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. This work was supported by grants from the Department of Health and Human Services (DHHS) of the Victorian State Government; the Australian Research Council (ARC; CE140100011, CE140100036) the National Health and Medical Research Council of Australia (NHMRC; 1113293, 2002317 and 1116530), and Medical Research Future Fund (MRFF) Awards (2005544, 2002073, 2002132). THON and AKW were supported by an NHMRC Emerging Leadership Level 1 Investigator Grants (#1194036), HV was supported by an NHMRC APPRISE Research Fellowship (1116530), KK was supported by the NHMRC Leadership Investigator Grant (1173871), DLL was supported by a NHMRC Principal Research Fellowship (#1137285), KS and DAW are supported by NHMRC Investigator Grants (1177174 and 1174555). KS also received support from the A2 Milk Company and the Jack Ma Foundation. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. DIG and SJK were supported by an NHMRC Senior Principal Research Fellowships (1117766).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human experimental work was conducted according to the Declaration of Helsinki Principles and the Australian National Health and Medical Research Council Code of Practice. All participants provided written informed consent prior to the study. The study was approved by the Alfred Hospital (#280/14), The University of Melbourne (#2056761, #2056689, #1442952, #1955465, #202121198153983 and #2020-20782-12450-1), Melbourne Health (HREC/68355/MH-2020, HREC/66341/MH-2020) and James Cook University (H7886) Human Research Ethics Committees. Plasma samples including COVID-19 acute/convalescent and vaccinated samples, were obtained from: The Alfred Hospital, University of Melbourne, James Cook University, The Royal Melbourne Hospital. Some samples obtained from The Royal Melbourne Hospital Department of Microbiology were part of a previously published patient cohort4 and patients C1, C2 and COVID-negative blood and plasma from the Burnet Institute. The vaccinee samples are collected under ethics number 2021-21198-15398-3 through the University of Melbourne.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 7 added to show that the COVID-19 NAb-testTM is capable of detecting neutralising antibodies following vaccination in human subjects. Figure 7 also provides a comparison of neutralising antibody measurements from fingerprick whole blood, venous whole blood and plasma, from same individuals.
Data Availability
All data referred to in the manuscript are available upon reasonable request
